| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70585
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-172
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2884
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2839
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-08 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 |
| filingDate |
2014-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2020-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2020-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-105377298-B |
| titleOfInvention |
A method of increasing GIPCR signaling in cells of a subject with scoliosis |
| abstract |
Provided herein is a method of increasing GIPCR signaling in cells of a subject in need thereof, the method comprising administering to the subject an effective amount of an inhibitor of integrin α5β1 expression and/or activity, comprising This increases GiPCR signaling in the cells of the subject. An inhibitor of integrin α5β1 can be, for example, an agent that inhibits the interaction between osteopontin (OPN) and integrin α5β1. Also provided are methods of determining risk of developing scoliosis based on the presence of at least one copy of the CD44 risk allele and methods of stratifying subjects with scoliosis and kits for performing these methods. Specifically, the method for determining risk identifies SNP rsl467558; an isoleucine to threonine mutation at position 230 of CD44. |
| priorityDate |
2013-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |